Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2045

Annual patent cliff calendar for 2045 — US pharmaceutical patents by expiration date.

Patents
1,566

Quick answer

1,566 indexed pharmaceutical patents have expiration dates in 2045. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 12414995

    Bifunctional compounds comprising Apcin-A and their use in the treatment of cancer

    Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12414983

    CD200AR ligands for cancer immunotherapy

    Regents of the University of Minnesota · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12414943

    Nimodipine parenteral administration

    Grace Therapeutics U.S., Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12415782

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12414942

    Compositions, methods, and systems for treating presbyopia

    LENZ THERAPEUTICS OPERATIONS, INC. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12414963

    Treatment of sleep-wake disorders and neurodegenerative disease comprising modified resistant maltodextrin

    Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12414953

    Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)

    Prelude Therapeutics, Incorporated · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12414934

    Combination therapies

    Aardvark Therapeutics, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12415995

    Bacterial toxins and uses thereof as Ras specific proteases for treating cell proliferation diseases and disorders

    Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12415867

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    The Board of Regents of the University of Oklahoma · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12415845

    Methods of producing T cell populations using hydroxycitric acid and/or a salt thereof

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12415863

    Compositions and methods for treating cancer

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12415861

    Anti C-MET antibodies

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12416008

    Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity using RNA aptamers

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12414981

    JNK inhibitors for use in treating and preventing neurodegenerative disorders

    Northwestern University · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12414911

    Topical compositions and methods of use

    MIRACLE FRUIT OIL L.L.C. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12414907

    Peptide having hair growth promoting activity and use thereof

    CAREGEN CO., LTD. · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 2025290040

    GAMMA DELTA T CELL COMPOSITIONS AND METHODS OF USE

    BEIGENE SWITZERLAND GMBH [CH] · Granted Thu Sep 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Sep 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12421287

    T-cell modulatory multimeric polypeptides and methods of use thereof

    Cue Biopharma, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12422364

    Fluorescence spectral shape analysis for analyte recognition

    The Board of Regents of the University of Texas System · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12421302

    CAR-t cells and autoimmune diseases

    The Regents of the University of California · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12421308

    Anti-G-CSF antibodies and uses thereof

    ME Therapeutics Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12421315

    CLL-1 targeted immunotherapies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12421525

    Conjugates comprising AAVs and CAS9 polypeptides

    The Regents of the University of California · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12421316

    Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12421310

    CD47 binding agents

    CENTESSA PHARMACEUTICALS (UK) LIMITED · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12421249

    Inhibitors of APOL1 and methods of using same

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12419958

    Clinical formulations

    Astellas Institute for Regenerative Medicine · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12420085

    Synergistic therapies for inter vertebral disc degeneration

    Discure Technologies Ltd · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12419895

    Methods for treating subjects with Prader-Willi syndrome

    ESSENTIALIS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12419942

    Use of the Salmonella spp type III secretion proteins as a protective vaccination

    The Board of Regents for Oklahoma State University · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12419866

    Compounds and methods for treating an epileptic disorder

    The Regents of the University of California · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12419888

    Methods of treating elevated plasma cholesterol

    INSTITUT DE CARDIOLOGIE DE MONTREAL · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12419880

    Companion diagnostic tool for mutant p53 reactivating compounds

    PMV PHARMACEUTICALS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12419811

    Hydrogel drug delivery composition

    BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12421317

    Polynucleotides encoding anti-glucagon-like peptide 1 receptor (GLP1R) antagonist antibodies

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12421188

    Heterocyclic compound and use thereof

    Takeda Pharmaceutical Company Limited · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12421251

    Cystic fibrosis transmembrane conductance regulator modulating agents

    Vertex Pharmaceuticals Incorporated · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12421512

    CRISPR/Cas screening platform to identify genetic modifiers of tau seeding or aggregation

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12421236

    Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor

    Medshine Discovery Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12421193

    GPR52 modulators and methods of use

    Neurocrine Biosciences, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12421220

    Bicyclic-substituted glutarimide cereblon binders

    C4 THERAPEUTICS, INC. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12421269

    SGLT2/DPP4 inhibitor and application thereof

    CGeneTech (Suzhou, China) CO., Ltd. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12421273

    Ectonucleotidase inhibitors and methods of use thereof

    ANTENGENE THERAPEUTICS LIMITED · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12421280

    Insulin like growth factor binding protein bioactive peptide fragments

    Northwestern University · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2045?

1,566 published patents in our USPTO index have expiration dates falling in calendar year 2045.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.